webinar cme top

ICUS ANYTIME is a comprehensive CEUS education portal
offering the convenience of online learning and free CME credits.

Learn basic and advanced CEUS from the experts!

CLICK HERE for upcoming live webinars

CLICK HERE for upcoming bubble conferences and other CEUS programs

CLICK HERE for archived ICUS webinars.


ICUS VIRTUAL EXHIBITS simulate the traditional exhibit experience
offered at live, in-person educational programs.

See how ultrasound products are used to improve CEUS and patient care.

CLICK HERE to visit our Virtual Exhibit Booths.


webinar cme bottom

Global Contrast-Enhanced Ultrasound (CEUS)

Click on any country shaded in orange to see the commercially available agent(s). Zoom to see smaller countries.
 

(Agent(s) commercially available)

 

 

(No agent commercially available at this time)

 

* See package inserts for approved indications. Note that this “Global CEUS” map lists certain ultrasound contrast agents under different product names (i.e., Lumason/SonoVue and Definity/Luminity). ICUS will update this map as additional agents are approved throughout the world.

 

ICUS does not endorse or recommend the use of any ultrasound contrast agent or other medical product. In addition, ICUS does not warrant the accuracy of information provided in package inserts or herein. Medical decisions are the sole responsibility of health care providers and their patients, who are encouraged to carefully evaluate all potential risks and benefits associated with the use of any medical product or procedure including ultrasound contrast agents and (CEUS).


Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents

Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents

October 12, 2021 — PNAS
Abstract
Type 1 diabetes (T1D) results from immune infiltration and destruction of insulin-producing β cells within the pancreatic islets of Langerhans (insulitis). Early diagnosis during presymptomatic T1D would allow for therapeutic intervention prior to substantial β-cell loss at onset. There are limited methods to track the progression of insulitis and β-cell mass decline. During insulitis, the islet microvasculature increases permeability, such that submicron-sized particles can extravasate and accumulate within the islet microenvironment. Ultrasound is a widely deployable (read more…)

GE Healthcare Receives FDA Approval for Change in Contraindications in Prescribing Information for OptisonTM

GE Healthcare Receives FDA Approval for Change in Contraindications in Prescribing Information for OptisonTM

October 05, 2021 — GE Healthcare – media release
(BUSINESS WIRE)  GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood products’ from the contraindications in its prescribing information for its product OptisonTM (Perflutren Protein-Type A Microspheres Injectable Suspension, USP).
Optison is an ultrasound enhancing agent (UEA) that can improve the visualization of the left ventricular border ─ an area of the heart that is critical to see (read more…)

Experts call for expanded use of ultrasound contrast agents

Experts call for expanded use of ultrasound contrast agents

October 1, 2021 — AuntMinnie.com
Authors:  Amerigo Allegretto, staff writer
Ultrasound experts at this week’s Advances in Contrast Ultrasound conference in Chicago called for expanded use of ultrasound contrast agents to offer patients broader access to what they said was low-cost, safe, and reliable diagnostic imaging.
 
Ultrasound contrast agents are biocompatible and injected during an ultrasound scan to enhance the resolution of an ultrasound image. They contain microscopic gas-filled microbubbles that reflect ultrasound signals as they flow through the body’s circulation and (read more…)

Doctors predict benefits of ultrasound enhancing agents

Doctors predict benefits of ultrasound enhancing agents

September 30, 2021
International Contrast Ultrasound Society (ICUS)
BUSINESS WIRE –  Doctors today described new ways to predict whether specific patients will benefit from the use of ultrasound enhancing agents (UEAs) to improve the accuracy of their ultrasound scan for diagnosis of heart disease, the number one killer of Americans.
 
“With increasing obesity and demographic trends that can interfere with ultrasound image quality, we are finding that the use of UEAs to salvage suboptimal images is not keeping up with the need for (read more…)

Experimental Study on the Compatibility and Characteristics of a Dual-Target Microbubble Loaded with Anti-miR-33

Experimental Study on the Compatibility and Characteristics of a Dual-Target Microbubble Loaded with Anti-miR-33

September 11, 2021 — International Journal of Nanomedicine
Abstract
Objective
To prepare a new type of dual-target microbubble loaded with anti-miR-33 (ANM33).
Methods
Carrier core nanobubbles (NBs) were prepared by thin film hydration, and microbubbles loaded with PM1 (PCNBs) were prepared by grafting DSPE-PEG2000-maleimide-PM1 onto the NB surface. ANM33 was connected via electrostatic adsorption and covalent bonding, and hyaluronic acid (HA) was covalently connected. PM1 and HA were the targets, and ANM33 was the intervention drug. To evaluate the general physical and chemical properties of (read more…)

The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma

The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma

September 9, 2021 — Journal of Ultrasound in Medicine
Abstract
Objectives
To retrospectively explore the value of contrast-enhanced ultrasound (CEUS) in differentiating small renal cell carcinomas (RCCs) from angiomyolipomas (AMLs), and distinguishing between clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC).
Methods and Analysis
A total of 151 patients with small renal masses (110 ccRCCs, 12 pRCCs, 9 chRCCs, and 20 AMLs) were enrolled between August 2016 and October 2019.
Results
There were significant differences in terms of enhancement intensity (EI), enhancement homogeneity, perilesional (read more…)

Value of Conventional Ultrasonography with Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Partial Cystic Thyroid Nodules

Value of Conventional Ultrasonography with Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Partial Cystic Thyroid Nodules

September 1, 2021 — Ultrasound in Medicine and Biology
Abstract
The value of contrast-enhanced ultrasonography (CEUS) in the diagnosis of malignant partial cystic thyroid nodules (PCTNs) remains unclear. Thus, in the present study, the data of patients with pathologically proven PCTNs who underwent CEUS in the Chinese PLA General Hospital from January 2016 to February 2019 were retrospectively reviewed, and the imaging characteristics of benign and malignant PCTNs were compared. A total of 177 PCTNs were enrolled in this study, including 58 (read more…)

Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma

Correlation Between Enhancement Patterns on Transabdominal Ultrasound and Survival for Pancreatic Ductal Adenocarcinoma

August 31, 2021 — Cancer Management and Research
Abstract
Objective
Investigate the CEUS enhancement patterns of PDAC and analyse correlations between the CEUS enhancement pattern and both the degree of tumour tissue differentiation and overall survival (OS).
Methods
The study included 56 patients with locally advanced PDAC, performed conventional ultrasound and CEUS, and analysed characteristics of the CEUS enhancement patterns. In addition, clinical data, such as serum level of CA19-9, TNM stage were collected, and patients’ survival times were followed up. TICs of dynamic CEUS (read more…)

Low-Intensity Focused Ultrasound Safe, Effective in Mild Alzheimer’s Disease

Low-Intensity Focused Ultrasound Safe, Effective in Mild Alzheimer’s Disease

August 30, 2021 — Medscape
By Pauline Anderson
A new noninvasive procedure is safe and effective for treating patients with mild Alzheimer’s disease (AD), new research suggests.
The approach uses MRI-guided low-intensity focused ultrasound (FUS) and injected microbubbles to temporarily open the blood-brain barrier (BBB).
In a small group of patients, the procedure was significantly associated with reduced amyloid plaque and cognitive decline.
Being able to cross the BBB “on demand” and in a safe way opens up numerous frontiers for treating not only AD (read more…)

Contrast ultrasound can predict treatment failure of bone fractures

Contrast ultrasound can predict treatment failure of bone fractures

August 25, 2021 — AuntMinnie.com
By Amerigo Allegretto, staff writer
Contrast-enhanced ultrasound (CEUS) can predict treatment failure for bone fractures that fail to heal, according to a German study published August 22 in Ultrasound in Medicine and Biology.
Researchers led by Dr. Julian Doll from Heidelberg University Hospital in Germany found that CEUS can detect perfusion differences between consolidating and persistent nonunion fractures and can predict treatment failure as early as 12 weeks after surgery.
“Our results prove that CEUS can … predict (read more…)